• Skip to main content
  • Skip to footer
cnb1383_liver-model-drug-safety_webinar_nav-ad_v1
  • About us
  • News
  • Events
  • Careers
cn-bio-organ-on-a-chip-logo
  • Products
    • PhysioMimix® OOC Microphysiological Systems
    • Consumables
      • PhysioMimix® multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
    • Organ-on-a-chip models
    • Gut/Liver-on-a-chip
    • Lung-on-a-chip
    • Support packages
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Technology
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers in Biotech
  • Contact us

Explore our solutions


PhysioMimix® is a suite of hardware, consumables and assay protocols that enable you to recreate complex human biology and accurately predict human drug responses.

PhysioMimix OOC

physiomimix-single-and-multi-organ-on-a-chip-systems
Learn more

Consumables

Multi-chip plates
3D validated cells
NASH-in-a-box
Bioavailability assay kit: Human 18
DILI assay kit: Human 24
Learn more

Models

Single-organ models
- Liver-on-a-chip model
- Lung-on-a-chip model
Multi-organ models
- Gut/Liver-on-a-chip models

Support packages

PhysioMimix® support packages

Discover the applications


Investigate the application areas that our PhysioMimix® products and services support

Learn more

Disease modeling

Metabolic dysfunction-associated steatohepatitis
Hepatitis B
Pulmonary infection
Learn more

Safety toxicology

Drug-induced liver injury
Immune-mediated liver injury
Learn more

ADME

Drug absorption
Drug metabolism
Drug bioavailability
Oligonucleotide delivery
Learn more

Studies as a service


Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

Learn more
icon-nash-1-150x150.png MASLD/MASH
icon-dili-tox-150x150.png Drug-induced liver injury
icon-adme-150x150.png ADME

Liver-on-Chip and In Silico Modeling for Quantitative Drug Metabolism Studies

August 9, 2021

Resource > Webinars >

Liver-on-Chip and In Silico Modeling for Quantitative Drug Metabolism Studies


For Quantitative Drug Metabolism Studies

Filed under: ADME and Drug metabolism

web s4e1 |

Video content if present

Liver-on-Chip and In Silico Modeling

for Quantitative Drug Metabolism Studies


Watch this webinar to learn:

  • Various applications of Liver-on-a-Chip in quantitative PK
  • CYP (Cytochrome P450) and UGT (Uridine Diphosphate-glucuronosyltransferase) metabolism with Liver-on-a-Chip
  • Combining in silico modeling and experimental data for in vitro–in vivo extrapolation
  • Liver-on-a-Chip and future perspectives

This webinar examines the benefits of combining Liver-on-a-chip with in silico modeling to explore clinical PK predictions of specific reference drugs, including investigations into the intrinsic clearance determinations for high metabolically stable compounds and the quantitation of fractions metabolized by specific enzymes.

Understanding the pharmacokinetics (PK) of new drugs has typically relied quite heavily on animal models, however, these models are expensive and often have limited relevance to humans. The development of a Liver-on-a-Chip (LOAC) device, that better recapitulates human physiology compared to standard in vitro systems, represents a promising alternative to reduce the use of animal models.


View our Q&A document from the live event.


Speaker Information:

milanoDr Nicolo Milano

Postdoc Scientist
Hoffman-La Roche, Basel Switzerland

Video content if present

Speak to our experts

Request a meeting with one of our OOC experts to see how our products and services can support your studies

Request a meeting

Footer

CN Bio logo

332 Cambridge Science Park, Milton Road
Cambridge, CB4 0WN

UK: +44 (0) 1223 737 941

US: +1 415 523 4005

Privacy | Cookies | Regulatory | Accessibility
Website terms | Terms of sale

Product Recycling

©2025 CN Bio Innovations Ltd
Registered No. ‍06517359. VAT No. GB978184563

Latest news

  • Microphysiological systems for mAbs development: how do they address animal limitations? May 1, 2025
  • Why the FDA animal testing phase-out for monoclonal antibodies? May 1, 2025
  • NIH to prioritize human-based research technologies & reduce animal use in research April 29, 2025
Cyber Essentials Logo